<?xml version="1.0" encoding="UTF-8"?>
<p>As of June 2020, two phase III open-label trials (SIMPLE) are underway recruiting patients from countries with high infection rates/burden.
 <sup>
  <xref rid="B13" ref-type="bibr">13</xref>,
  <xref rid="B17" ref-type="bibr">17</xref>
 </sup> The first trial is evaluating the safety and efficacy of remdesivir in hospitalized patients with severe COVID-19 infection, having oxygen saturation&lt;94% and radiological proof of pneumonia. The second trial includes confirmed cases with moderate manifestations of COVID-19. Both studies have similar intravenous dosing regimens of 5-day and 10-day duration of therapy.
</p>
